BIOCYTOGEN
15.9.2022 14:03:42 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ras Al Khaimah Ruler Awards Sheikh Saud International Prize for Materials Science at IWAM 20264.2.2026 14:09:00 CET | Press release
Prize underscores Emirate’s global commitment to science, innovation and advanced materials research His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, today awarded the Sheikh Saud International Prize for Materials Science during the 17th International Workshop on Advanced Materials (IWAM), one of the world’s leading forums for advanced materials research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204274737/en/ HH Sheikh Saud bin Saqr Al Qasimi-keynote speech at IWAM (Photo: AETOSWire) Presented on day two of IWAM, the Prize recognizes exceptional contributions to materials science and its applications in addressing global challenges. The award was conferred upon Professor Omar Yaghi, winner of the 2025 Nobel Prize in Chemistry, in recognition of his transformative work in materials chemistry and his pioneering contributions to clean energy, carbon capture and sustai
Positron AI Raises $230 Million Series B at Over $1 Billion Valuation to Scale Energy-Efficient AI Inference4.2.2026 14:00:00 CET | Press release
Co-led by ARENA Private Wealth, Jump Trading, and Unless, with strategic investment from Qatar Investment Authority (QIA), Arm, and HelenaFunding accelerates Positron's roadmap from shipping Atlas systems today to next-generation Asimov silicon, targeting tape-out in late 2026 and production in early 2027; announced at Web Summit Qatar Positron AI, the leader in energy-efficient AI inference hardware, today announced an oversubscribed $230 million Series B financing at a post-money valuation exceeding $1 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204250472/en/ Thomas Sohmers (L), CTO and cofounder, and Mitesh Agrawal (R), CEO of Positron AI (Credit: Kavita Agrawal) The round was co-led by ARENA Private Wealth, Jump Trading, and Unless, and includes new and strategic investment from Qatar Investment Authority (QIA), Arm, and Helena. Existing investors Valor Equity Partners, Atreides Management, DFJ Growth, Res
Bridger Photonics Posts Record Year as Operators Turn to Trusted Emissions Intelligence4.2.2026 13:20:00 CET | Press release
Bridger Photonics (“Bridger”) closed its strongest year in company history last year, marked by record asset coverage, record revenue, and global adoption of its methane emissions data and intelligence across multiple continents and the entire oil and natural gas value chain. Bridger’s momentum reflects a clear shift in how operators choose to manage emissions: away from legacy and weather-limited approaches and toward entire asset coverage with data they can trust. Bridger continues to lead the methane detection space—growing existing customers and attracting new ones. Bridger has competitively displaced 32 customers from other aerial technologies, driven by deep industry expertise, proven data reliability and actionability, the ability to operate across challenging conditions and seasons, close coordination with ground crews, and a white-glove service model designed around operator needs. Customers across onshore production, midstream, LNG, and offshore operations are increasingly re
Registrar Corp Acquires TechniCAL and Becomes the Global Compliance Leader in Shelf-stable Packaged Foods Safety4.2.2026 13:00:00 CET | Press release
Registrar Corp, the world’s largest food and beverage regulatory compliance provider, today announced its acquisition of TechniCAL, the world’s leading independent Process Authority for low-acid and acidified foods. Registrar Corp is a Paine Schwartz Partners portfolio company. Consumer demand for convenience and longer product life without refrigeration has driven rapid growth in shelf-stable foods and beverages, with packaging innovations extending beyond cans and glass jars to formats such as retort pouches and cartons. Ensuring products in these various packaging formats are safe from harmful microorganisms is critical to public health and required by the U.S. FDA. Together, Registrar Corp and TechniCAL provide the industry’s most complete solution, combining proven scientific expertise, regulatory knowledge, training, and advanced thermal testing. “TechniCAL is world renowned for its Process Authority expertise and advanced testing technologies assuring compliant thermal processin
Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid4.2.2026 13:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable under the rules of the Toronto Stock Exchange (the “TSX”). The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential dec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom